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Diagnostic criteriaAims: Guidelines recommend hemoglobin A1c (HbA1c) as a diagnostic test for type 2
diabetes, but its accuracy may differ in certain ethnic groups.
Methods: The prevalence of type 2 diabetes by HbA1c, fasting glucose, and 2 h glucose was
compared in 3016 participants from Chennai and Delhi, India from the CARRS-2 Study to
757 Indians in the U.S. from the MASALA Study. Type 2 diabetes was defined as fasting
glucose  7.0 mmol/L, 2-h glucose  11.1 mmol/L, or HbA1c  6.5%. Isolated HbA1c
diabetes was defined as HbA1c  6.5% with fasting glucose < 7.0 mmol/L and 2 h
glucose < 11.1 mmol/L.
Results: The age, sex, and BMI adjusted prevalence of diabetes by isolated HbA1c was 2.9%
(95% CI: 2.2–4.0), 3.1% (95% CI: 2.3–4.1), and 0.8% (95% CI: 0.4–1.8) in CARRS-Chennai,
CARRS-Delhi, and MASALA, respectively. The proportion of diabetes diagnosed by isolated
HbA1c was 19.4%, 26.8%, and 10.8% in CARRS-Chennai, CARRS-Delhi, and MASALA0322, USA.
la@nm.org
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aya@ucsf.
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metabolic risk than those diagnosed by fasting or 2-h measures.
Conclusions: In Asian Indians, the use of HbA1c for type 2 diabetes diagnosis could result in
a higher prevalence. HbA1c may identify a subset of individuals with milder glucose
intolerance.
 2019 Elsevier B.V. All rights reserved.1. Introduction
Measurement of fasting plasma glucose (FPG) and/or 2-h post
challenge glucose (2hPG) levels have traditionally been the
cornerstone of the diagnosis of diabetes mellitus (DM) [1]. In
2009 an international expert committee recommended the
use of HbA1c as an additional diagnostic criterion for DM [2]
and it is now recommended as a diagnostic tool by both the
American Diabetes Association and the World Health Organi-
zation [3,4]. While HbA1c is now often used in clinical prac-
tice, it is possible that the pathophysiological mechanisms
of type 2 diabetes development may differ in those identified
by HbA1c compared to fasting or 2-h glucose measures, and
its accuracy as a diagnostic tool has not been well tested in
populations such as Asian Indians, a group with particularly
high type 2 diabetes risk [5,6]. We aimed to compare HbA1c
as a diagnostic tool with fasting plasma glucose and 2- post-
challenge glucose measurements in assessing the prevalence
of type 2 diabetes in two South Asian populations. One popu-
lation was from two geographic centers in India (from the
Center for cArdio-metabolic Risk Reduction in South Asia
(CARRS-2) study) [7], and the other from two geographic cen-
ters in the United States (from theMediators of Atherosclero-
sis in South Asians Living in America (MASALA) study) [8].
2. Methods
We conducted a cross-sectional analysis of data from two
large, population-based cohorts, one in India and one in the
United States. In total, 1568 participants living in Chennai,
India and 1448 participants living in New Delhi, India from
the CARRS-2 Study were compared with 757 Asian Indian
immigrants in the MASALA Study.
2.1. Description of participants
2.1.1. The CARRS-2 study
In brief, CARRS-2 is a multi-site cross-sectional study recruit-
ing participants from the cities of Chennai and New Delhi in
India and Karachi in Pakistan. Study design and recruitment
for CARRS-2 was methodically akin to that of CARRS-1 which
was conducted in 2010–2011 [7]. For the purposes of this study
we analyzed data only from the Chennai and New Delhi sites
in order to limit our analysis to Asian Indians. This was done
in order to remain in accordance with MASALA which had
very few participants with origins from Pakistan. Recruitment
occurred between September 2014 and March 2016. A multi-
stage random sampling technique was used to select house-
holds for participation in order to be representative of Delhiand Chennai. In order to reduce selection bias, two adults,
onemale and one female, aged 20 years or older were selected
from each household. In households with more than two eli-
gible members, the ‘‘Kish method” was applied to determine
enrollment [9]. Recruitment, enrollment, and data collection
were collected through three visits to each participant’s place
of residence. In order to maintain valid comparisons with
MASALA, we excluded participants who were younger than
age 40 and/or who had existing cardiovascular disease as
ascertained through self-report. Pregnant women and bed-
ridden individuals were excluded from study enrollment [7].
Demographic and behavioral information including lan-
guage use, medical history, current medication use, and use
of alcohol and tobacco were obtained using standardized
questionnaires administered by trained interviewers. Physical
activity was assessed using the Global Physical Activity
Questionnaire (GPAQ). Blood pressure was assessed using an
electronic sphygmomanometer (Omron HEM-7080 and HEM-
7080IT-E; Omron Corporation, Tokyo, Japan). Three seated
measurements were taken, and an average of the three was
used to assess systolic and diastolic blood pressure. After an
8–12 h overnight fast, a 75 g oral glucose tolerance test (OGTT)
was administered to participants without previously diag-
nosed diabetes who were willing and able to participate.
Blood samples were obtained from a peripheral vein just
before glucose ingestion (fasting) and at 30 min and 2-h post
glucose challenge for plasma glucose measurements. The
samples were transported from field sites in cold chain to
the laboratories for analysis. Both accredited laboratories in
Delhi and Chennai participated in a Randox International
Quality Assessment Scheme (RIQAS) that standardized find-
ings to a central laboratory at the All India Institute of Medical
Sciences (AIIMS) in Delhi. Blood samples were analyzed on
the same day as they were collected. For the three cities
together (including Karachi, Pakistan), response rates were
94.7% for questionnaire completion and 84.3% for bio-
specimens. Total cholesterol was measured by enzymatic
colorometric cholesterol oxidase peroxidase method, high-
density lipoprotein cholesterol by direct method, and
triglycerides by enzymatic methods using Roche/Boehringer-
Mannheim Diagnostics. Low-density lipoprotein cholesterol
cholesterol was calculated using Friedewald’s formula.
Plasma glucose was measured by hexokinase/kinetic
method, and glycated hemoglobin (HbA1c) was measured by
high performance liquid chromatography (HPLC). Insulin
was measured using the electro chemiluminescence immune
assay (ECLIA). Participant weight was measured using body
composition analyzers (Tanita BC-601), and height was
measured using a portable stadiometer (SECA-213). BMI was
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squared. Waist circumference was measured using a non-
stretch measuring tape (SECA-201) at the site of maximum
circumference halfway between the lower ribs and the ante-
rior superior iliac spine.
2.1.2. MASALA study
The design, sampling strategy, recruitment, enrollment, and
both questionnaire and examination components of the
MASALA study have been described previously [8]. Briefly,
MASALA is a community-based sample of South Asian Amer-
icans living in the greater San Francisco Bay and Chicago
areas. Participants were aged 40–84 years, and are without
previously known cardio-vascular disease. Recruitment
occurred between October 2010 and March 2013. All partici-
pants were screened by telephone and were invited to either
the University of California, San Francisco, or the Northwest-
ern University clinical field center for a 6-h baseline clinical
examination [8].
South Asian ethnicity was self-reported and defined as
having 3 or more grandparents born in either India, Pakistan,
Nepal, Bangladesh, or Sri Lanka. However, for the purposes of
this study in order to remain in accordance with CARRS, we
limited our sample to the 757 individuals who were born in
India specifically. Individuals with previous diagnosis of heart
attack, stroke, transient ischemic attack, heart failure, angina,
nitroglycerin medication use, any prior cardiovascular proce-
dures, current arterial fibrillation, cancer treatment, short-
ened life expectancy, impaired cognition, plans to move out
of the geographic area of the study site in the next five years,
living in a nursing home, or weight > 300 lb were excluded
from study enrollment [8].
Demographic and behavioral information including lan-
guage use, medical history, current medication use, and use
of alcohol and tobacco were obtained using standardized
questionnaires administered by trained interviewers. Physical
activity was assessed using the Typical Week’s Physical Activ-
ity Questionnaire [10]. After a 5-minute seated rest, blood
pressure was assessed using an automated blood pressure
machine (V100 Vital Sign Monitor; GE Healthcare, Fairfield,
CT, USA). Three seated measurements were taken, and an
average of the last two readings was used to assess systolic
and diastolic blood pressure. After at least a 9 h overnight
fast, a 75 g oral glucose load was administered to participants
without previously diagnosed diabetes who were willing to
participate. Blood samples were obtained from a peripheral
vein just before glucose ingestion (fasting) and at 30 min
and 2-h post glucose challenge. Plasma glucose was mea-
sured using the hexokinase method. Fasting serum samples
were batched for insulin measured by the sandwich
immunoassay method (Roche Elecys 2010; Roche Diagnostics,
Indianapolis, IN). HbA1c was measured using the immunotur-
bidimetry assay. Total cholesterol, triglycerides, and high den-
sity lipoprotein cholesterol were analyzed using enzymatic
methods and low-density lipoprotein cholesterol was calcu-
lated using the Friedewald equation.
Participant weight was measured using a standing balance
beam scale or digital weighing scale, and height was measured
using a stadiometer. BMI was calculated as weight in kilograms
divided by height in meters squared. Waist circumference wasmeasured by trained study staff using a non-stretch tape mea-
sure at the site of maximum circumference halfway between
the lower ribs and the anterior superior iliac spine. Two mea-
sures were taken and the average was used for analysis. Com-
puted tomography (CT) scans of the abdomen (Philips Medical
Systems, Andover, MA; Toshiba Medical Systems, Tustin, CA;
Siemens Medical Solution Malvern, PA) were used to assess vis-
ceral, subcutaneous, and intermuscular fat mass. Non-contrast
cardiac CT images using a cardiac-gated CT scanner (UCSF:
Phillips 16D scanner or Toshiba MSD Aquillion 64; NWU: Sei-
mens Sensation Cardiac 64 Scanner) were obtained to assess
pericardial fat volume and hepatic fat attenuation.
2.1.3. Informed consent and ethics committee approval
The CARRS-2 study was approved by the Institutional Review
Boards of the Public Health Foundation of India, New Delhi,
All India Institute of Medical Sciences, New Delhi, Madras
Diabetes Research Foundation, Chennai, India, Aga Khan
University, Karachi, Pakistan, and Emory University, Atlanta,
USA [7]. The MASALA Study was approved by both the Univer-
isty of California San Francisco and Northwestern University
Institutional Review Boards [8].
2.2. Definition of type 2 diabetes
In order to assess the prevalence of newly diagnosed type 2 dia-
betes by glycemicmeasure, we excluded individuals with a pre-
viously known diagnosis of diabetes who were taking any
glucose lowering medication (n = 1728 for CARRS and n = 124
for MASALA). We further excluded those who were missing
fasting glucose, 2-h glucose or HbA1c data from the CARRS-2
(n = 6880) and the MASALA (n = 28) cohorts. A new laboratory
diagnosis of type 2 diabetes was made if fasting glu-
cose  7.0mmol/L, 2-h post challenge glucose  11.1 mmol/L
and/or HbA1c 6.5%. Isolated fasting type 2 diabetes was
defined as fasting glucose  7.0mmol/L; HbA1c < 6.5%; and
2 h glucose < 11.1 mmol/L. Isolated 2-h post challenge type 2
diabetes was defined as 2 h glucose  11.0 mmol/L; fasting
glucose < 7.0 mmol/L, HbA1c < 6.5%. Isolated HbA1c type 2
diabetes was defined as HbA1c 6.5%; fasting glucose <
7.0mmol/L and 2 h glucose < 11.1mmol/L [3]. Normal glucose
tolerance was defined as those participants who had both
fasting plasma glucose < 5.6 mmol/l and a 2 h post-challenge
glucose < 7.8 mmol/l, as well as HbA1c < 5.7% [3].
2.3. Calculations
Beta-cell function was estimated by the oral disposition index
(DIo) and was calculated as (DI0-30/DG0-30) * (1/fasting insulin)
[11], and by HOMA-b, [20*I0(mIU/ml) / G0 (mmol/l)- 3.5] [12].
HOMA-IR was used tomeasure insulin resistance and calculated
as [I0(mIU/ml) * G0 (mmol/l)/22.5] [12]. Given that fasting and 30-
minute insulin measures were not available for the CARRS-2
Chennai site, we calculated disposition index, HOMA-b and
HOMA-IR for the CARRS-2 Delhi and MASALA sites only.
2.4. Statistical analysis
Prevalence values and 95% confidence intervals were esti-
mated by glucose measure and study site. Participant charac-
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mic measure and study site and were compared by study
using chi-squared test or ANOVA as appropriate. The non-
normally distributed variables were log transformed. The
effect of isolated HbA1c on the odds of type 2 diabetes com-
pared to normal glucose tolerance or prediabetes was
assessed using standardized logistic regression. Initially, a
regression model was created to compare the odds of having
diabetes diagnosed by isolated HbA1c compared to no dia-
betes after adjusting for age and sex. Subsequent multivari-
able models were then created to adjust for additional
variables including education physical activity smoking sta-
tus, body mass index, blood pressure, cholesterol triglyc-
erides, insulin resistance, beta-cell function, and vegetarian
diet. In MASALA, an additional model was run to adjust for
adiponectin, resistin, and ectopic fat. All analyses were per-
formed using SAS Version 9.4 (SAS Institute, Cary, NC).
3. Results
Table 1 provides details on the prevalence of type 2 diabetes
by diagnostic criterion and study site. The age, sex, and BMI
adjusted prevalence of any newly diagnosed type 2 diabetes
was 18.2% (95% CI: 15.8–20.9) in CARRS-2 Chennai, 14.0%
(95% CI: 12.0–16.4) in CARRS-2 Delhi, and 12.5% (95% CI: 9.6–
16.4) in MASALA. If using isolated elevated HbA1c to define
type 2 diabetes, the age, sex, and BMI adjusted prevalence
was 2.9% (95% CI: 2.2–4.0), 3.1% (95% CI: 2.3–4.1), and 0.8%
(95% CI: 0.4–1.8) in CARRS-Chennai, CARRS-Delhi, and
MASALA, respectively. In both sites in India, the prevalence
of type 2 diabetes diagnosed by HbA1c was greater than the
prevalence as diagnosed by fasting glucose or 2-h post chal-
lenge glucose. Fig. 1 provides details about the proportion of
diabetes diagnosed by each glycemic measure by study site.Table 1 – Age, sex, and BMI adjusted prevalence of glycemic sta
CARRS-2 Chennai
n 1568
Lab diagnosis of DM n = 242
18.2%
(95% CI: 15.8–20.9)
FPG  126 mg/dl n = 136
9.4%
(95% CI: 7.8–11.2)
PPG  200 mg/dl n = 172
12.3%
(95% CI: 10.5–14.5)
HbA1c  6.5% n = 181
12.9%
(95% CI: 11.0–15.1)
Isolated FPG  126 mg/dl n = 10
0.6%
(95% CI: 0.3–1.1)
Isolated PPG  200 mg/dl n = 40
2.7%
(95% CI: 1.9–3.6)
Isolated HbA1c  6.5% n = 47
2.9%
(95% CI: 2.2–4.0)In CARRS-2 Chennai, 19.4% of type 2 diabetes cases were diag-
nosed by isolated HbA1c, while 26.8% of type 2 diabetes cases
were diagnosed by isolated HbA1c in CARRS-2 Delhi. In
MASALA, 10.8% of the new type 2 diabetes cases were diag-
nosed by isolated elevated HbA1c.
Participant characteristics by glycemic status and study
population are shown in Tables 2 and 3. In CARRS-2, com-
pared to those with type 2 diabetes diagnosed by either the
fasting or 2-h glucose criteria, those with type 2 diabetes as
diagnosed solely by HbA1c were significantly older, with a
greater proportion consuming a vegetarian diet. They also
had lower mean systolic and diastolic blood pressure, fasting
glucose, 30-minute glucose, 2- post challenge glucose, HbA1c
value and triglycerides. In a subset of individuals from the
Delhi site only, those with type 2 diabetes diagnosed by iso-
lated HbA1c had significantly lower HOMA-IR, higher
HOMA-b, and higher mean disposition index compared to
those with type 2 diabetes diagnosed by either of the glucose
measures. We compared the characteristics of type 2 diabetes
diagnosed by isolated elevated HbA1c to type 2 diabetes diag-
nosed by HbA1c and with either glucose criterion in CARRS-2
participants (Supplemental Table 1). Those diagnosed by
HbA1c and a glucose criterion more closely resembled those
diagnosed by fasting or 2-h glucose measures compared to
those diagnosed by isolated elevated HbA1c.
In MASALA (Table 3), we compared the clinical characteris-
tics of those with type 2 diabetes by either the fasting or 2-h
glucose criteria to those with type 2 diabetes as diagnosed
by isolated HbA1c. Those with type 2 diabetes classified by
isolated HbA1c had a significantly lower mean fasting glu-
cose, 30-minute post-challenge glucose, 2-h glucose, lower
cholesterol, and greater mean HOMA-b and resistin than
those diagnosed by fasting or 2-h measures. HOMA-IR was
significantly lower in those with type 2 diabetes diagnosedtus in the CARRS-2 and MASALA study.
CARRS-2 Delhi MASALA
1448 608
n = 190 n = 74
14.0% 12.5%
(95% CI: 12.0–16.4) (95% CI: 9.6–16.4)
n = 99 n = 19
7.0% 3.3%
(95% CI: 5.7–8.7) (95% CI: 2.1–5.4)
n = 108 n = 63
7.6% 11.2%
(95% CI: 6.2–9.3) (95% CI: 8.4–14.1)
n = 139 n = 35
9.6% 5.4%
(95% CI: 8.0–11.5) (95% CI: 3.7–7.8)
n = 19 n = 0
1.3% 0.0%
(95% CI: 0.8–2.1) (95% CI: 0.0–0.0)
n = 26 n = 36
1.8% 5.8%
(95% CI: 1.2–2.6) (95% CI: 4.0–8.6)
n = 51 n = 8
3.1% 0.8%
(95% CI: 2.3–4.2) (95% CI: 0.3–1.9)
HbA1c HbA1c
HbA1c
Fasting 
Glucose 
Fasting 
Glucose 
Fasting 
Glucose 
2-Hour 
Glucose 
2-Hour 
Glucose 
2-Hour 
Glucose 
10
(4%)
47
(19%)
102
(42%)
40
(17%)
19
(8%)
13
(5%)
11
(5%)
51
(27%)
62
(33%)
19
(10%)
26
(14%)6
(3%)
14
(7%)
12
(6%)
8
(11%)
13
(18%)
3
(4%)
3 (4%)
Figure legend:  A: CARRS-2, Chennai; B:  CARRS-2, Delhi; C: MASALA
A B
C
11
(15%)
36
(49%)
Fig. 1 – Proportion of diabetes diagnosed by glycemic measure and study site.
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glucose, however it was not significantly different in those
diagnosed by 2-h glucose. Fasting insulin was significantly
higher in those with type 2 diabetes diagnosed by fasting glu-
cose, but was not significantly different in those diagnosed by
2-h glucose compared to those diagnosed by HbA1c. There
were no significant differences in ectopic fat measures
between those with type 2 diabetes diagnosed by isolated
HbA1c compared to fasting or 2-h glucose measures. As with
CARRS, those diagnosed by HbA1c and another glucose crite-
rion in MASALA more closely resembled those diagnosed by
fasting or 2-h glucose measures compared to those diagnosed
by isolated HbA1c (Supplemental Table 2).
In the CARRS-2 study, using backwards stepwise regres-
sion models including age, sex, education, physical activity,
smoking status, vegetarian diet, BMI, waist circumference,
systolic and diastolic blood pressure, and HDL, LDL, and
triglycerides, only age (OR 1.03; 95% CI: 1.01, 1.06) and waist
circumference (per cm, OR 1.02; 95% CI: 1.00, 1.04) were signif-
icantly associated with type 2 diabetes diagnosed by isolated
HbA1c compared to no diabetes. In a subset of individuals
from the Delhi site only, after additional adjustment for
HOMA-IR, HOMA-b, and Disposition Index, only waist circum-
ference (OR 1.03; 95% CI: 1.01, 1.06), HOMA-IR (OR 1.31; 95% CI:
1.06, 1.62), and HOMA-b (OR 0.99; 95% CI: 0.98, 0.99) were asso-
ciated with having type 2 diabetes diagnosed by HbA1c as
opposed to not having diabetes.Despite the small sample with isolated elevated HbA1c
in MASALA (n = 8), waist circumference (OR 1.09; 95% CI:
1.01, 1.68), HOMA-IR (OR: 2.30, 95% CI: 1.13, 4.67), and
HOMA-b (OR 0.97; 95% CI: 0.94, 0.99) were significantly asso-
ciated with the odds of having type 2 diabetes diagnosed by
HbA1c after adjusting for all other relevant covariates in the
model.
4. Discussion
In two population-based studies of Asian Indians living in
India and the United States, we found that the prevalence
of type 2 diabetes was highest when diagnosed by HbA1c, fol-
lowed by 2-h post challenge glucose, and then fasting glucose
measures in those living in India, and was highest by 2-h post
challenge glucose in those living in the United States. We also
found that between 1.3% and 3.5% of Asian Indiansmet type 2
diabetes criteria solely due to an elevated HbA1c.
The prevalence of type 2 diabetes diagnosed by isolated
elevated HbA1c varies by race/ethnicity, and may be higher
in populations of Asian descent. In our two Asian Indian pop-
ulations, we found a prevalence between 1.3 and 3.5%. Stud-
ies in other Asian populations also found a prevalence of
isolated HbA1c diagnosed type 2 diabetes, similar to the range
we found in our study. A study from Korea found a type 2 dia-
betes prevalence of 2.1% when using isolated HbA1c as the
diagnostic criterion [13], while a study in Filipino Americans,
Table 2 – Age, sex, and BMI adjusted participant characteristics by glycemic status-CARRS-combined Chennai and Delhi.
Normal glucose
tolerance
DM by FPG DM by 2-h glucose Isolated
HbA1c% 6.5%
N (%) 1054 (49.9) 235 (8.2) 280 (10.0) 98 (3.0)
Age (years) 48.7 (8.1)* 50.4 (7.5)* 50.9 (8.3)* 53.6 (8.6)
Men (%) 47.2 52.3 56.6 53.4
Vegetarian diet 28.0 20.6* 20.8* 32.3
Bachelor’s degree or higher (%) 18.7* 13.3 10.7* 20.9
Income category (%)
Tertile 1 38.7* 39.0 35.8 29.4
Tertile 2 23.7 28.1 28.7 23.0
Tertile 3 37.6* 32.9* 35.1* 47.7
Physical activity category (MET-min/week) (%)
<600 23.8 20.7 24.4 27.5
600–4000 60.7 69.8* 65.4 56.1
4000–8000 13.1 8.0 8.2 13.7
>=8000 2.3 1.5 2.0 2.7
Current smoker (%) 21.7 25.5 22.3 24.0
Blood pressure lowering medication use (%) 12.7* 15.4 18.4 20.4
Lipid lowering medication use (%) 3.5 2.6 2.6 3.1
BMI, kg/m2 25.1 (0.1)* 27.5 (0.3) 27.8 (0.3) 28.3 (0.5)
Waist Circumference, cm 88.4 (0.2)* 91.0 (0.5) 91.2 (0.4) 90.8 (0.7)
Systolic blood pressure, mmHg 128.5 (0.6) 137.2 (1.3)* 138.0 (1.1)* 130.0 (2.0)
Diastolic blood pressure, mmHg 81.9 (0.4) 86.1 (0.8)* 86.4 (0.7)* 83.0 (1.2)
Fasting glucose, mmol/L 5.0 (0.05)* 10.0 (0.07)* 9.1 (0.8)* 6.1 (0.2)
30 min glucose, mmol/L 7.8 (0.08)* 15.6 (0.1)* 14.8 (0.1)* 10.8 (0.3)
2-h glucose, mmol/L 5.5 (0.1)* 16.5 (0.2)* 16.8 (0.1)* 7.9 (0.4)
HbA1c, % 5.3 (0.03)* 8.1 (0.05)* 7.8 (0.04)* 6.6 (0.1)
HbA1c, mmol/L 34.6 (0.3)* 65.3 (0.5)* 61.5 (0.5)* 49.1 (1.1)
†Fasting insulin, pmol/L 58.3 (0.03)* 99.6 (0.1)* 92.3 (0.1)* 84.2 (0.1)
Median (IQR) 56.2 (35.4–84.3) 114.9 (76.7–116.7) 114.8 (70.2–166.7) 103.2 (72.0–146.3)
†HOMA-IR 1.9 (0.03)* 5.8 (0.1)* 4.9 (0.06)* 3.3 (1.2)
Median (IQR) 1.8 (1.2–2.7) 6.2 (4.2–10.5) 5.8 (3.9–9.0) 4.1 (2.7–5.9)
†HOMA-b 111.3 (0.03)* 53.0 (0.1)* 60.2 (0.1)* 97.4 (0.1)
Median (IQR) 105.5 (66.6–159.3) 64.0 (36.3–96.1) 74.0 (39.4–131.2) 127.3 (78.9–164.4)
†Disposition index 3.0 (0.05)* 0.3 (0.1)* 0.3 (0.1)* 1.0 (0.2)
Median (IQR) 2.8 (1.7–4.8) 0.3 (0.2–0.5) 0.3 (0.2–0.5) 0.8 (0.5–1.3)
†Total cholesterol 4.6 (0.01)* 5.1 (0.01)* 5.0 (0.01)* 4.9 (0.02)
Median (IQR) 5.2 (5.1–5.3) 5.3 (5.1–5.4) 5.3 (5.1–5.4) 5.3 (5.1–5.4)
†HDL, mmol/L 1.1 (0.01) 1.0 (0.04) 1.0 (0.01)* 1.1 (0.07)
Median (IQR) 1.1 (1.0–1.3) 1.0 (0.9–1.2) 1.0 (0.9–1.2) 1.1 (0.9–1.2)
†LDL, mmol/L 2.8 (0.01)* 3.0 (0.02) 3.0 (0.02)* 2.9 (0.03)
Median (IQR) 2.8 (2.3–3.3) 3.1 (2.5–3.7) 3.0 (2.5–3.7) 3.0 (2.6–3.9)
†Triglycerides, mmol/L 1.3 (0.01)* 2.0 (0.03)* 1.9 (0.3)* 1.6 (0.05)
Median (IQR) 1.2 (0.9–1.7) 2.0 (1.3–2.8) 1.9 (1.3–2.7) 1.5 (1.2–2.1)
Data are given as %, mean (SD), or.
† Geometric mean (SD) with median and interquartile range.
* P < 0.05 vs. isolated HbA1c  6.5.
 Data are from a subset that includes the Delhi site only.
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diabetes prevalence of 2.7% by isolated HbA1c [14].
The results of our study are similar to those of a previous
study comparing the prevalence of type 2 diabetes by glyce-
mic measures in Asian Indians living in Chennai [15]. In this
study, the prevalence of type 2 diabetes diagnosed by HbA1c
was 110% and 27% higher than the prevalence of type 2 dia-
betes as diagnosed by the fasting glucose and 2-h post chal-
lenge glucose criteria respectively [15]. The current study
adds to these findings by including a population from another
city in India as well as a migrant Asian Indian population to
the United States, thereby indicating that these findings areassociated with race/ethnic background rather than geo-
graphical location. Furthermore, a study examining the
effects of type 2 diabetes definition on global diabetes preva-
lence using a pooled analysis of 96 population-based studies
found that while in general type 2 diabetes prevalence based
on HbA1c was lower than the prevalence based on fasting or
2-h plasma glucosemeasures, in the subgroup of studies from
South Asia, the prevalence of type 2 diabetes based on HbA1c
was higher than those based on fasting or 2-h measures [16].
Similarly, a supplemental analysis of South Asians, Blacks,
and Whites from a study in the U.K. showed that South
Asians had a higher prevalence of HbA1c diagnosed type 2
Table 3 – Age, sex, and BMI adjusted participant characteristics by glycemic status-MASALA.
Normal glucose
tolerance
DM by FPG DM by 2-h glucose Isolated
HbA1c% 6.5%
N (%) 134 (28.3) 19 (3.3) 63 (11.4) 8 (1.9)
Age (years) 51.6 (8.9) 56.3 (8.3) 55.8 (8.2) 54.5 (9.6)
Men (%) 49.4 83.5 46.1 64.5
Vegetarian diet (%) 47.6 23.3 43.6 37.4
Bachelor’s degree or higher (%) 93.1 98.9 81.7 83.7
Income category (%)
<$40 k 10.0* 6.2* 16.7* 48.4
$40–75 k 11.1 10.4 12.2 15.4
$75–100 k 12.3 18.1 12.0 0.1
>100 k 66.6 65.4 59.1 36.0
Physical activity category (MET-min/week) (%)
600–4000 4.0 0 0 0
4000–8000 36.4 32.0 29.1 13.6
>=8000 59.5 67.8 71.3 87.6
Current smoker (%) 3.1 3.7 1.7* 15.5
Blood pressure lowering medication use (%) 26.1 30.6 29.9 26.8
Lipid lowering medication use (%) 12.7 10.1 20.1 14.5
AHEI-2010 component score 70.3 (0.6) 69.6 (1.6) 69.9 (0.9) 70.1 (2.7)
BMI, kg/m2 25.2 (0.4) 27.9 (1.0) 26.9 (0.6) 27.9 (1.8)
Waist circumference, cm 90.1 (0.6)* 93.1 (1.5) 93.1 (0.8) 97.8 (2.6)
Systolic blood pressure, mmHg 121.7 (1.5) 127.2 (3.7) 128.5 (2.0) 126.8 (6.4)
Diastolic blood pressure, mmHg 71.8 (0.9) 75.9 (2.3) 75.4 (1.3) 78.0 (3.9)
Fasting glucose, mmol/L 5.0 (0.08)* 8.4 (0.1)* 6.5 (0.1)* 5.7 (0.3)
30 min glucose mmol/L 7.8 (0.2) 13.1 (0.4)* 11.1 (0.2)* 9.2 (0.7)
2-h glucose, mmol/L 5.7 (0.3) 15.3 (0.6)* 13.6 (0.3)* 7.7 (1.2)
HbA1c, % 5.4 (0.05)* 7.3 (0.1) 6.5 (0.1) 6.9 (0.2)
HbA1c, mmol/L 35.8 (0.5)* 56.3 (1.2) 47.8 (0.7) 51.7 (2.3)
†Fasting Insulin, pmol/L 45.9 (0.05)* 78.8 (0.1)* 63.7 (0.07) 64.1 (0.2)
Median (IQR) 46.0 (35.0–61.0) 90.1 (56.0–132.0) 71.7 (44.7–111.0) 72.1 (50.3–83.1)
†HOMA-IR 1.7 (0.05)* 4.8 (0.1)* 3.0 (0.07) 2.7 (0.2)
Median (IQR) 1.7 (1.3–2.3) 5.5 (3.4–8.6) 3.4 (1.9–5.5) 3.1 (2.4–3.7)
†HOMA-b 108.4 (0.05)* 57.4 (0.1)* 81.4 (0.07)* 97.4 (0.2)
Median (IQR) 114.5 (76.5–154.1) 63.0 (35.4–92.6) 93.4 (59.7–126.6) 93.6 (73.0–126.2)
†Disposition Index 3.6 (0.08)* 0.3 (0.2) 0.8 (0.1) 1.0 (0.3)
Median (IQR) 3.4 (2.3–5.7) 0.3 (0.2–0.6) 0.9 (0.5–1.3) 0.8 (0.7–1.3)
†Total Cholesterol, mmol/L 4.7 (0.02) 5.2 (0.04)* 5.0 (0.02)* 4.8 (0.07)
Median (IQR) 4.8 (4.3–5.3) 5.4 (4.5–5.9) 5.1 (4.5–5.6) 4.6 (4.3–5.2)
†HDL, mmol/L 1.3 (0.02) 1.2 (0.05) 1.2 (0.03) 1.2 (0.09)
Median (IQR) 1.3 (1.1–1.6) 1.0 (1.0–1.6) 1.2 (1.0–1.4) 1.2 (0.9–1.4)
†LDL, mmol/L 2.8 (0.02) 2.9 (0.07) 2.9 (0.04) 2.8 (0.1)
Median (IQR) 2.8 (2.4–3.4) 3.0 (2.6–3.5) 3.0 (2.6–3.4) 2.8 (3.3–2.5)
†Triglycerides, mmol/L 1.1 (0.04)* 1.8 (0.1) 1.6 (0.05) 1.4 (0.2)
Median (IQR) 1.2 (0.8–1.5) 1.8 (1.4–2.6) 1.6 (1.3–2.1) 1.6 (1.1–1.8)
†Apo-B, g/L 0.8 (0.02) 0.9 (0.05) 0.9 (0.03) 0.8 (0.09)
Median (IQR) 0.8 (0.7–0.9) 0.9 (0.8–1.0) 0.9 (0.7–1.0) 0.8 (0.7–0.9)
†Adiponectin (ng/ml) 11.9 (0.06)* 8.5 (0.2) 8.2 (0.08) 7.8 (0.3)
Median (IQR) 12.9 (7.8–17.0) 6.5 (4.4–10.3) 8.5 (6.0–12.1) 7.9 (4.9–11.4)
†Resistin (ng/ml) 17.2 (0.07)* 19.9 (0.2)* 19.8 (0.1)* 26.7 (0.3)
Median (IQR) 18.8 (16.4–24.6) 19.6 (17.7–23.6) 18.7 (16.0.5–23.5) 17.7 (16.3–25.8)
Subcutaneous fat area (cm2) 229.6 (7.3) 259.2 (18.2) 251.9 (10.0) 270.3 (32.3)
Visceral fat area (cm2) 113.5 (4.0)* 128.6 (10.3) 130.9 (5.7) 146.7 (17.1)
Hepatic fat attenuation (HU) 59.4 (0.9) 51.8 (2.3) 50.8 (1.3) 54.4 (3.9)
Pericardial fat volume (cm3) 49.2 (2.1) 63.1 (5.4) 61.8 (3.0) 52.6 (9.0)
Intramuscular fat area (cm2) 19.6 (0.7) 16.4 (1.9) 20.1 (1.1) 23.5 (3.1)
Total lean mass area (cm2) 91.0 (1.5) 92.2 (3.9) 93.6 (2.2) 86.7 (6.4)
Data are given as %, mean (SD), or.
† Geometric mean (SD) with median and interquartile range.
* P < 0.05 vs. isolated HbA1c  6.5.
 Data are from a restricted sample that includes only participants with adiponectin, resistin, and visceral fat mass measurements (N = 516
participants).
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compared to other ethnic groups [17] thereby indicating that
this particularly high type 2 diabetes prevalence based on
the HbA1c assay may be a phenomenon unique to Asian
populations.
Furthermore, while HbA1c has been shown to have high
specificity but limited sensitivity for type 2 diabetes diagnosis
in White, African American, Mexican American, and Brazilian
populations compared to fasting and 2-h post challenge glu-
cose measures [18,19], this may not be the case in certain
Asian populations, where HbA1c may be overly sensitive with
higher false positives.
It is also possible that in populations of Asian Indian decent,
the isolated HbA1c criteria for diabetes diagnosis may identify
individuals with milder glucose intolerance compared to those
diagnosed with fasting or 2-h measures. In CARRS-2, partici-
pants with isolated HbA1c had significantly lower fasting and
30-minute, and 2-h glucose measures as well as lower mean
triglyceride, lower HOMA-IR, and higher HOMA-b and disposi-
tion index measures compared to those with type 2 diabetes
diagnosed by fasting or 2 h glycemia. In MASALA, individuals
with type 2 diabetes diagnosed by isolated HbA1c had lower
2-h glucose, total cholesterol, and Apo-B and higher HOMA-b
compared to those with type 2 diabetes diagnosed by fasting
or 2 h glucose measures. In addition, they also had lower fast-
ing and 30-minute glucose aswell as lower HOMA-IR compared
to those with type 2 diabetes diagnosed by fasting glucose.
These results are similar to a study from Chennai, India which
found that participants diagnosed by the HbA1c criterion had
milder glucose intolerance and lower serum triglyceride levels
than those diagnosed by fasting or 2-h post challengemeasures
[15]. In aggregate, these findings suggest that individuals with
isolated elevated HbA1c may represent either a different sub-
group of type 2 diabetes, an earlier phase in the natural history
of type 2 diabetes development, or a possiblemisdiagnosis. Fur-
thermore, recognizing that the relationship between HbA1c
and glucose measures may differ by race/ethnicity has clinical
relevance for minimizing the risks of over or under-treatment
of diabetes and related complications [20].
Our study directly compared differences in type 2 diabetes
prevalence by diagnostic criteria using two populations of
Asian Indians. While there were differences in the sampling
frames and socio-demographic characteristics between
MASALA and CARRS-2, both studies are large population-
based samples with similar laboratory and anthropometric
measures and are representative of Asian Indians in large
urban centers in India or the United States. However, the
results of our study should be interpreted in the context of
several limitations. Given that our study directly compares
two distinct Asian Indian populations from large metropoli-
tan cities (the greater San Francisco and Chicago areas of
the U.S. and Chennai and Delhi India) the results cannot be
generalized to Asian Indians living in other parts of the U.S.
or India. Additional limitations to our study include the exclu-
sion of participants under the age of 40 and also those with
pre-existing cardiovascular disease. Furthermore, the primar-
ily cross-sectional nature of our study makes it impossible to
determine temporality between the prevalence of type 2 dia-
betes as diagnosed by isolated HbA1c and the associated
covariates. Measures of insulin sensitivity and secretion wereassessed by fasting surrogate measures, and therefore may
not be completely accurate. However, these results suggest
milder defects in insulin secretion and resistance in Asian
Indians diagnosed with diabetes by HbA1c compared to fast-
ing or 2 h glucose measures, and should be tested in further
studies using gold-standard procedures. In addition, HbA1c
was measured by different methods in the CARRS and
MASALA studies, which may possibly explain the somewhat
different prevalence of diabetes diagnosed by isolated HbA1c
in the two cohorts. However, since that the pattern of a higher
prevalence of diabetes diagnosed by isolated HbA1c compared
to other measures was seen in both cohorts, it is not likely
that the different assay measures affected the overall results.
HbA1c measures are also influenced by several conditions
such as the presence of iron deficiency anemia [21]. There-
fore, the lack of data regarding circulating iron and vitamin
B12 in our study is an important limitation, and future studies
should examine the influence of iron and B12 levels on the
prevalence of HbA1c diagnosed diabetes in Asian Indian pop-
ulations. Lastly, various factors such as hemoglobin variants
may affect the accuracy of HbA1c measurements according
to the assay method used [22]. Therefore knowledge and
awareness of hemoglobin variants affecting HbA1c measure-
ments in a given population is critical when determining
whether this measure is appropriate as a diagnostic tool [22].
Our findings suggest that while the prevalence of type 2 dia-
betes diagnosed by isolated elevated HbA1c is fairly low, this is
still a substantial proportion of all type 2 diabetes that is iden-
tified by this method. Furthermore, individuals diagnosed with
type 2 diabetes by isolated HbA1c had milder glucose intoler-
ance, and significantly lower serum triglycerides than those
diagnosed by fasting or 2-h post challenge measures. While
HbA1c is generally considered a more specific test for type 2
diabetes screening then fasting or 2 h glucose measures, this
may not be the case in Asian Indian individuals. Furthermore,
the use of a solo test may not be the best strategy to diagnosed
diabetes. While the combination of a 2-h glucose test and
HbA1c would likely capture the highest number of people with
diabetes, this strategy may not be practical given the burden-
some nature of the oral glucose tolerance test. Given that
HbA1c is becoming an increasingly utilized tool clinically for
type 2 diabetes diagnosis, these results prompt the need for
comprehensive studies examining the diagnostic accuracy
and outcomes of the different glycemic measures, particularly
in Asian Indian populations. In addition, future longitudinal
studies are needed in order to ascertain the long-term implica-
tions of a high prevalence of elevated isolated HbA1c on type 2
diabetes related morbidity and mortality.
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